- A patient is prescribed ciprofloxacin for a urinary tract infection. The patient also takes a daily calcium carbonate supplement for osteoporosis. If both are taken simultaneously by mouth, which statement best describes the resulting interaction?
Answer: A pharmacokinetic interaction occurs in the GI tract where polyvalent cations from the supplement form an insoluble chelate with ciprofloxacin, reducing its absorption.
The correct answer describes a classic pharmacokinetic interaction based on chelation. Fluoroquinolones, like ciprofloxacin, and tetracyclines can bind with polyvalent cations (e.g., Ca2+, Mg2+, Al3+, Fe2+) in the gastrointestinal tract to form insoluble chelate complexes. This process prevents the antibiotic from being absorbed into the systemic circulation, leading to subtherapeutic drug levels and potential treatment failure. For this reason, administration should be separated by several hours.
A is incorrect; the interaction is pharmacokinetic (absorption), not pharmacodynamic (at the bacterial target).
B describes a plausible mechanism for other drugs (like some proton pump inhibitors), but fluoroquinolones are not particularly acid-labile.
D describes an incorrect pharmacokinetic mechanism and consequence.
- This adverse event is most likely caused by a drug interaction between:
Answer: Clarithromycin and atorvastatin, a pharmacokinetic interaction where clarithromycin inhibits CYP3A4, leading to increased atorvastatin levels.
The correct answer identifies the well-known interaction between macrolide antibiotics and certain statins. Atorvastatin is extensively metabolized by the cytochrome P450 enzyme CYP3A4. Clarithromycin is a potent inhibitor of CYP3A4. Co-administration leads to a significant decrease in the first-pass metabolism of atorvastatin, resulting in much higher plasma concentrations. Elevated statin levels are associated with an increased risk of myopathy and the most severe form, rhabdomyolysis, which matches the patient's presentation.
A describes an incorrect mechanism.
B describes an interaction that does exist (clarithromycin also inhibits warfarin metabolism), but the patient's symptoms (rhabdomyolysis) point directly to statin toxicity, not a bleeding complication.
D describes an incorrect interaction; lisinopril does not affect atorvastatin clearance in this manner.
- Which of the following co-administered drugs and mechanisms would most likely explain the development of methotrexate toxicity?
Answer: Probenecid, via a pharmacokinetic interaction that inhibits the organic anion transporters (OATs) in the renal tubules, decreasing methotrexate excretion.
The correct answer identifies a significant pharmacokinetic interaction affecting excretion. Methotrexate is primarily cleared from the body by active secretion into the renal tubules via transporters like OATs. Probenecid is a potent inhibitor of these transporters. By blocking OATs, probenecid can markedly decrease the renal clearance of methotrexate, leading to a prolonged half-life and accumulation to toxic levels.
B is incorrect. Leucovorin (folinic acid) is used as a rescue agent to reduce methotrexate toxicity by bypassing the DHFR enzyme block; it does not potentiate the effect.
C is incorrect. Methotrexate is not significantly metabolized by CYP enzymes. Some proton pump inhibitors can interfere with methotrexate clearance, but the mechanism is inhibition of renal transporters, not CYP induction.
D is incorrect because while penicillins can also inhibit renal secretion of methotrexate, the primary effect of displacement from protein binding is a transient increase in the free fraction, not total concentration, and the major interaction is at the level of renal excretion.
- Which combination of interactions best explains this exaggerated response?
Answer: Pharmacodynamic synergism at the GABA-A receptor, combined with a pharmacokinetic interaction where acute alcohol intake inhibits diazepam metabolism.
The correct answer acknowledges both a key pharmacodynamic and a key pharmacokinetic interaction. Pharmacodynamically, both ethanol and benzodiazepines like diazepam are positive allosteric modulators of the GABA-A receptor, the primary inhibitory neurotransmitter receptor in the CNS. Their combined action leads to synergistic CNS depression. Pharmacokinetically, while chronic alcohol use induces CYP enzymes, acute high-dose alcohol consumption can competitively inhibit CYP enzymes (like CYP3A4 and 2C19) that metabolize diazepam, slowing its clearance and prolonging its effects. The combination of these two mechanisms explains the profound sedation.
A is incorrect; the interaction is synergistic, not antagonistic, and while chronic induction is a factor, acute inhibition is more relevant to this scenario.
B is incorrect; diazepam is cleared by hepatic metabolism, not primarily renal excretion.
D is incorrect because the interaction is not purely pharmacodynamic, and the agents act on the same receptor complex, not unrelated pathways.
- This change in blood pressure is most likely due to which type of interaction?
Answer: A pharmacodynamic interaction in which naproxen inhibits prostaglandin synthesis, leading to afferent arteriole vasoconstriction and sodium retention.
The correct answer describes a physiological antagonism, which is a type of pharmacodynamic interaction. NSAIDs like naproxen inhibit cyclooxygenase (COX) enzymes, reducing the synthesis of renal vasodilating prostaglandins. This leads to vasoconstriction of the afferent arteriole of the glomerulus and increased renal sodium and water retention. Both effects counteract the blood pressure-lowering effects of ACE inhibitors like lisinopril.
A is incorrect because this is not a known pharmacokinetic interaction; the mechanism is pharmacodynamic.
C describes an incorrect pharmacodynamic mechanism. Naproxen does not interact with angiotensin II receptors.
D describes an incorrect pharmacokinetic mechanism. Lisinopril is not significantly protein-bound, so displacement is not a relevant mechanism.
- Which statement most accurately describes the initial pharmacokinetic and clinical consequence for Drug X immediately following administration of Drug Y?
Answer: The percentage of free Drug X will transiently increase, potentially leading to an immediate increase in therapeutic or toxic effects.
The correct answer describes the immediate effect of protein binding displacement. When Drug Y displaces Drug X, the amount of unbound (free) Drug X in the plasma momentarily increases. For a highly bound drug (99%), even a small displacement can double the free concentration (e.g., from 1% to 2%). Since the free drug is the pharmacologically active portion, this can lead to an acute increase in the drug's effect, potentially causing toxicity. This effect is transient because the increased free fraction is now available for metabolism and excretion, which will eventually lead to a new steady state with a lower total drug concentration but a similar free drug concentration. However, the initial spike is the period of greatest clinical risk.
B is incorrect; total concentration decreases over time, not immediately.
C is incorrect; displacement from plasma proteins increases the apparent volume of distribution as more drug can move into the tissues.
D is incorrect; clearance mechanisms act on the free drug, so an increase in free fraction will initially increase the rate of clearance.
- Which statement accurately predicts the primary pharmacokinetic consequence and the necessary action?
Answer: Verapamil inhibits P-glycoprotein in the gut and kidneys, which will increase digoxin's bioavailability and decrease its renal clearance; the digoxin dose should be reduced.
The correct answer identifies a major pharmacokinetic interaction. Digoxin is a substrate for the efflux transporter P-glycoprotein (P-gp) in the intestinal wall, kidneys, and other tissues. Verapamil is a potent inhibitor of P-gp. By inhibiting P-gp in the intestine, verapamil increases digoxin absorption. By inhibiting P-gp in the renal tubules, it decreases digoxin secretion. Both mechanisms lead to a significant increase in digoxin serum concentration, necessitating a dose reduction of digoxin (often by 30-50%) to avoid toxicity.
B incorrectly states that verapamil is an inducer.
C describes a pharmacodynamic interaction that does occur, but the question asks about the primary pharmacokinetic consequence, and the digoxin dose must be adjusted.
D is incorrect because digoxin is minimally metabolized by CYP enzymes; its clearance is dominated by renal excretion via P-gp.
- Which statement best describes the interaction responsible for the change in INR?
Answer: A pharmacokinetic interaction where rifampin, a potent enzyme inducer, significantly increases the metabolic clearance of warfarin via CYP2C9.
The correct answer identifies the well-established pharmacokinetic interaction between rifampin and warfarin. Rifampin is one of the most potent inducers of cytochrome P450 enzymes, including CYP2C9 which is the primary enzyme responsible for metabolizing the more potent S-enantiomer of warfarin. Induction of CYP2C9 leads to a greatly accelerated rate of warfarin metabolism, a lower plasma concentration, and a subtherapeutic INR, increasing the risk of thrombosis.
A describes a plausible but incorrect pharmacodynamic mechanism. Rifampin does not directly affect clotting factor synthesis.
B describes protein displacement, which is another type of pharmacokinetic interaction. However, the primary and most clinically significant interaction with rifampin is potent enzyme induction, not protein displacement.
D describes an absorption interaction (chelation), which is not the mechanism for the rifampin-warfarin interaction.
- Which statement most accurately describes the interaction responsible for the patient's symptoms?
Answer: A pharmacokinetic interaction occurred, as components in grapefruit juice irreversibly inhibit intestinal CYP3A4, increasing simvastatin bioavailability.
The correct answer describes the classic interaction between grapefruit juice and CYP3A4 substrates. Simvastatin undergoes extensive first-pass metabolism in the intestinal wall by CYP3A4. Furanocoumarins in grapefruit juice are mechanism-based (suicide) inhibitors of intestinal CYP3A4, meaning they irreversibly inactivate the enzyme. This dramatically reduces first-pass metabolism, leading to a several-fold increase in the oral bioavailability and systemic exposure to simvastatin, which increases the risk of concentration-dependent adverse effects like myopathy.
A incorrectly states that grapefruit juice is an inducer; it is a potent inhibitor.
B describes an incorrect pharmacodynamic mechanism.
D is incorrect; this interaction is most significant for orally administered drugs that have high first-pass metabolism via CYP3A4.
- What is the fundamental mechanism of this critical drug interaction?
Answer: A pharmacodynamic interaction where nitrates and sildenafil act on different steps of the cGMP pathway, leading to a synergistic and profound vasodilation.
The correct answer describes a classic and dangerous pharmacodynamic interaction. Both drugs cause vasodilation via the nitric oxide/cyclic guanosine monophosphate (cGMP) pathway. Nitrates (like isosorbide mononitrate) increase the synthesis of cGMP by activating guanylate cyclase. Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor, which prevents the breakdown of cGMP. The combined effect is a synergistic and massive accumulation of cGMP, leading to profound vasodilation, severe hypotension, and potentially fatal cardiovascular collapse.
A is incorrect; the mechanism is pharmacodynamic, not pharmacokinetic.
B describes an incorrect pharmacodynamic mechanism; the drugs do not act on the same receptor, but on different enzymes in the same signaling pathway.
C describes an incorrect pharmacokinetic mechanism.
- What is the most likely underlying mechanism for this patient's presentation?
Answer: A pharmacodynamic interaction whereby furosemide-induced hypokalemia increases the sensitivity of the Na+/K+-ATPase pump to inhibition by digoxin.
The correct answer describes a classic, indirect pharmacodynamic interaction. Furosemide is a loop diuretic that can cause significant potassium loss, leading to hypokalemia. Digoxin exerts its effect by inhibiting the Na+/K+-ATPase pump. Potassium and digoxin compete for the same binding site on this pump. When potassium levels are low (hypokalemia), there is less competition for digoxin, leading to increased digoxin binding and an exaggerated pharmacologic (and toxic) effect, even at therapeutic serum concentrations.
A describes a pharmacokinetic mechanism that is not the primary interaction between these two drugs.
C describes an incorrect pharmacokinetic mechanism; tissue displacement is not the issue.
D describes an incorrect pharmacodynamic mechanism; the drugs act on entirely different targets (the Na+/K+/2Cl- cotransporter for furosemide and the Na+/K+-ATPase for digoxin).
- The observed change in tacrolimus levels is best explained by:
Answer: A pharmacokinetic interaction where St. John's Wort, a potent inducer of CYP3A4 and P-glycoprotein, has increased the clearance of tacrolimus.
The correct answer identifies a well-documented pharmacokinetic interaction. Tacrolimus is a substrate of both the metabolic enzyme CYP3A4 and the efflux transporter P-glycoprotein, both of which are highly expressed in the gut and liver. St. John's Wort is a potent inducer of both CYP3A4 and P-glycoprotein. By inducing these systems, St. John's Wort significantly increases both the first-pass and systemic metabolism and clearance of tacrolimus, leading to subtherapeutic blood levels and the risk of allograft rejection.
B incorrectly states that St. John's Wort is an inhibitor.
C describes a pharmacodynamic mechanism, but the observed change in drug levels clearly points to a pharmacokinetic interaction.
D describes an incorrect pharmacokinetic mechanism; the effect is on metabolism and transport, not glomerular filtration.
- The diminished response to albuterol is best explained by:
Answer: A pharmacodynamic interaction due to competitive antagonism, where propranolol blocks beta-2 adrenergic receptors in bronchial smooth muscle.
The correct answer describes a classic pharmacodynamic interaction at the receptor level. Albuterol is a beta-2 adrenergic receptor agonist; its binding to these receptors in the lungs causes bronchodilation. Propranolol is a non-selective beta-adrenergic antagonist, meaning it blocks both beta-1 and beta-2 receptors. By blocking the beta-2 receptors in the bronchial smooth muscle, propranolol directly opposes and prevents the therapeutic effect of albuterol. This is a competitive antagonism.
A is incorrect as the interaction is pharmacodynamic, not pharmacokinetic.
C describes an implausible mechanism; the primary interaction is direct receptor blockade in the target tissue.
D describes a pharmacokinetic mechanism that is not clinically significant for this drug pair.
- Drug interactions involving CYP450 enzyme inhibition can have opposite clinical consequences depending on the nature of the substrate drug. Which of the following statements accurately describes this principle?
Answer: Inhibition of an enzyme that converts a prodrug to an active metabolite will decrease the drug's effect, whereas inhibition of an enzyme that inactivates an active drug will increase its effect.
This statement correctly outlines the critical distinction between prodrugs and active drugs in the context of enzyme inhibition. If a drug is administered in an active form and metabolism leads to inactivation, inhibiting that metabolism will cause the active drug to accumulate, increasing its effect and potential for toxicity. Conversely, if a drug is administered as an inactive prodrug that requires metabolic activation, inhibiting the activating enzyme will prevent the formation of the active metabolite, leading to a decrease in the drug's therapeutic effect.
B is incorrect because accumulation of an inactive parent prodrug does not lead to a therapeutic or toxic effect.
C is incorrect as many important prodrugs (e.g., clopidogrel, codeine, tamoxifen) rely on CYP450 enzymes for their activation.
D is incorrect because by increasing the amount of drug that escapes first-pass metabolism, enzyme inhibition can dramatically increase Cmax (peak effect), not just the duration of action.
- What is the most likely mechanism underlying this adverse clinical event?
Answer: A pharmacokinetic interaction where omeprazole inhibits the CYP2C19 enzyme, preventing the metabolic activation of the prodrug clopidogrel.
The correct answer describes a critical pharmacokinetic interaction. Clopidogrel is a prodrug that requires bioactivation to its active metabolite by the cytochrome P450 enzyme CYP2C19. Omeprazole is a known inhibitor of CYP2C19. By inhibiting this enzyme, omeprazole reduces the formation of the active clopidogrel metabolite, leading to diminished antiplatelet effect and an increased risk of thrombotic events.
A is incorrect because the interaction is pharmacokinetic (affecting metabolism), not pharmacodynamic (affecting the receptor site). Omeprazole does not bind to the P2Y12 receptor.
B is incorrect because omeprazole is an inhibitor, not an inducer, of the relevant enzyme. Induction would cause faster metabolism, but inhibition causes slower metabolism/activation.
D describes an incorrect pharmacodynamic mechanism; while pH changes can affect drug absorption, they do not cause a pro-thrombotic state in this manner.
- This adverse event is the result of which of the following mechanisms?
Answer: A pharmacokinetic interaction where hydrochlorothiazide-induced sodium depletion leads to increased proximal tubular reabsorption of lithium.
The correct answer describes the primary pharmacokinetic interaction between thiazide diuretics and lithium. Thiazides inhibit sodium reabsorption in the distal convoluted tubule, leading to increased sodium excretion (natriuresis). The body compensates for this sodium loss by increasing the reabsorption of sodium in the proximal tubule. Because lithium ions are handled similarly to sodium ions in the proximal tubule, their reabsorption is also increased, leading to decreased renal clearance of lithium and a subsequent rise in serum levels to toxic concentrations.
A is incorrect because the mechanism is pharmacokinetic (related to excretion), not pharmacodynamic.
B is incorrect because lithium is a simple ion and is not metabolized by the liver; it is cleared almost exclusively by the kidneys.
C is incorrect because lithium is not significantly bound to plasma proteins.
- Which of the following best describes the primary mechanism for the increased bleeding risk with this combination?
Answer: A synergistic pharmacodynamic interaction, as both drugs impair hemostasis through independent mechanisms (anticoagulation and anti-platelet effects).
The correct answer identifies the primary pharmacodynamic interaction. Warfarin inhibits the synthesis of vitamin K-dependent clotting factors, impairing the coagulation cascade. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) in platelets, preventing the formation of thromboxane A2 and thus inhibiting platelet aggregation. Because these drugs disrupt two different and crucial components of hemostasis (clotting factors and platelets), their combined effect on bleeding risk is synergistic (greater than the sum of their individual effects).
A is incorrect; while high-dose salicylates can inhibit warfarin metabolism, this is not the primary mechanism, especially with low-dose aspirin.
C describes protein binding displacement, which is a minor and transient effect compared to the major PD interaction.
D describes an incorrect pharmacokinetic mechanism.
- This clinical scenario is a classic example of which type of interaction?
Answer: A pharmacodynamic interaction resulting in a synergistic increase in synaptic serotonin levels, leading to serotonin syndrome.
The correct answer describes the pharmacodynamic basis of serotonin syndrome. Sertraline is a selective serotonin reuptake inhibitor (SSRI), which increases synaptic serotonin by blocking its reabsorption. Phenelzine is a monoamine oxidase inhibitor (MAOI), which increases synaptic serotonin by preventing its breakdown. When used together, these two distinct mechanisms produce a synergistic and dangerous elevation of serotonin levels, leading to the clinical toxidrome of serotonin syndrome.
A is incorrect. While MAOIs can inhibit some CYP enzymes, the primary mechanism of this life-threatening interaction is pharmacodynamic, not pharmacokinetic.
C describes an incorrect pharmacokinetic mechanism.
D describes an incorrect pharmacodynamic mechanism; sertraline does not bind to the MAO enzyme.
- The lack of analgesic efficacy is most likely due to which type of drug interaction?
Answer: A pharmacokinetic interaction where fluoxetine, a potent CYP2D6 inhibitor, prevents the metabolic conversion of codeine to its active metabolite, morphine.
The correct answer describes the pharmacokinetic basis for this interaction. Codeine is a prodrug that exerts most of its analgesic effect after being metabolized into morphine. This conversion is primarily carried out by the CYP2D6 enzyme. Fluoxetine (and its active metabolite, norfluoxetine) is a potent inhibitor of CYP2D6. By inhibiting the enzyme, fluoxetine blocks the activation of codeine, leading to low morphine levels and a lack of analgesic effect.
A is incorrect; the mechanism is PK, not PD. Fluoxetine does not block opioid receptors.
B is incorrect as fluoxetine is an inhibitor, not an inducer, of CYP2D6.
C describes a plausible-sounding but incorrect PD mechanism. The primary interaction is the well-documented PK effect on codeine's activation.
